Effect of excessive activation of PI3K signaling pathway on the prognosis of patients with non-Hodgkin lymphoma and the efficacy of targeted drugs

VernacularTitle:PI3K信号通路过度激活对非霍奇金淋巴瘤患者预后的影响及其靶向药物疗效
Author: Wei QIAO ; Teng SONG ; Xinrui CHEN ; Huaqing WANG
From: Journal of International Oncology 2021;48(2):121-124
CountryChina
Language:Chinese
Abstract: The over-activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/mechanistic target of rapamcyin (mTOR) pathway is closely related to the occurrence, development and clinical prognosis of malignant tumors. Taking this signal pathway as a target can effectively inhibit tumor progression. At present, the Food and Drug Administration of the United States has approved three drugs (CAL-101, BAY80-6946, IPI-145) for the treatment of recurrent and refractory indolent non-Hodgkin lymphoma, which demonstrates significant efficacy and a manageable safety profile.